The USPSTF's characterization of the evidence against screening as
being of "moderate or high certainty," and thus deserving of its D
rating, is a "critical error," suggest the authors, led by Sigrid
Carlsson, MD, PhD, from the Memorial-Sloan Kettering Cancer Center in
New York City and Göteborg University in Sweden.
The USPSTF did not competently assess the mortality benefit of
screening, the authors say, and this error alone casts doubt on their
grading of prostate-specific antigen (PSA) testing.
Read the full Medscape Medical News report here
(May require free sign-up)
